Skip to main content
生物谷 logo

生物谷 — Investor Relations & Filings

Ticker · 920266 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2023-05-11 Earnings Release
Country CN China
Listing Beijing Stock Exchange 920266

About 生物谷

https://www.bioon.com/

Bio-Valley specializes in the research, development, and manufacturing of botanical-based therapeutic solutions, with a primary focus on cardiovascular and cerebrovascular health. The company is a leader in the industrialization of Erigeron breviscapus (Dengzhanhua), a botanical resource used for treating ischemic stroke and its sequelae. Its core product portfolio includes Dengzhan Shengmai Capsules and Dengzhan Xixin Injection, which are utilized in clinical settings for their neuroprotective and microcirculation-improving properties. Bio-Valley maintains a comprehensive value chain encompassing botanical cultivation, standardized extraction, and large-scale production. By leveraging advanced extraction technologies and rigorous quality control, the company provides evidence-based solutions for chronic disease management and geriatric care.

Recent filings

Filing Released Lang Actions
投资者关系活动记录表
Earnings Release Classification · 90% confidence The document is an investor relations activity record for a 2022 annual report earnings explanation meeting held on May 11, 2023. It includes detailed Q&A about the company's 2022 financial performance, product sales, strategic plans, and other operational details. The document is about a performance explanation meeting rather than the full annual report itself. It is not a short announcement stating the report is attached or published, but a detailed transcript of the meeting content. This fits the definition of an Earnings Release (ER) or possibly a Call Transcript (CT). However, since it is an earnings explanation meeting (业绩说明会) rather than a full conference call transcript, and it focuses on financial results and Q&A, the best fit is Earnings Release (ER). The document length is under 5,000 characters but contains substantive Q&A and financial data, so it is not a mere announcement. Therefore, the classification is ER with high confidence. FY 2022
2023-05-11 Chinese
2022年年度报告业绩说明会预告公告
AGM Information Classification · 95% confidence The document is a notice announcing a scheduled performance explanation meeting related to the company's 2022 Annual Report. It references the actual 2022 Annual Report and its summary, which were previously disclosed, but this document itself is not the report. The document length is short (1123 characters) and it announces the date, time, and format of the meeting for discussing the annual report results. It does not contain financial statements or detailed financial data. According to the 'Menu vs Meal' rule, this is an announcement about a report-related event, not the report itself. Therefore, the appropriate classification is AGM Information (AGM-R), as it relates to an Annual General Meeting type event focused on the annual report performance explanation.
2023-05-08 Chinese
第四届监事会第十次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Yunnan Shengwu Gu Pharmaceutical Co., Ltd. It details the meeting date, attendance, and the approval of various proposals including the 2022 Supervisory Board Work Report, 2023 Business Plan, 2022 Financial Statements, 2023 Financial Budget, 2022 Profit Distribution Plan, reappointment of the accounting firm, and other related matters. The document references other announcements and reports published on the Beijing Stock Exchange website but does not itself contain the full financial reports or detailed financial data. The document is a formal announcement of meeting resolutions and approvals, not the actual reports or financial statements. Therefore, it fits best into the category of Regulatory Filings (RNS) as a general regulatory announcement of meeting resolutions and approvals without the full report content.
2023-04-25 Chinese
关于预计2023年日常性关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the expected related party transactions for the year 2023 by Yunnan Biological Valley Pharmaceutical Co., Ltd. It details the nature, estimated amounts, related parties, and approvals by the board and supervisory committee. It is not a full financial report but a disclosure of anticipated related party transactions, which is a regulatory announcement. The document length is 3164 characters, relatively short, and it does not contain comprehensive financial statements or detailed financial analysis. It is not an annual or interim report, nor an earnings release. It fits best as a Regulatory Filing (RNS) because it is a compliance disclosure about related party transactions, not a full report or announcement of voting results or capital changes.
2023-04-25 Chinese
监事会对《董事会关于2022年财务审计报告非标准审计意见专项说明的议案》的意见
Audit Report / Information Classification · 95% confidence The document is a formal announcement from the Supervisory Board regarding the company's 2022 audit report which contains a qualified opinion (保留意见审计报告). It discusses the auditor's findings and the Supervisory Board's stance on the Board of Directors' special explanation about the audit report. The content focuses on audit-related matters and the supervisory board's oversight role, without containing the full audit report or detailed financial statements. The document length is short (627 characters) and it serves as an announcement or commentary on the audit report rather than the report itself. Therefore, it fits best under Audit Report / Information (AR), which covers standalone audit reports and related explanations excluding full annual reports. FY 2022
2023-04-25 Chinese
信永中和会计师事务所关于云南生物谷药业股份有限公司2022年度非经营性资金占用及其他关联资金往来的专项说明
Regulatory Filings
2023-04-25 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.